These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20075143)

  • 1. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
    Read PA; Khan FZ; Heck PM; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2010 Mar; 3(2):195-201. PubMed ID: 20075143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.
    Read PA; Khan FZ; Dutka DP
    Heart; 2012 Mar; 98(5):408-13. PubMed ID: 21561896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
    Read PA; Hoole SP; White PA; Khan FZ; O'Sullivan M; West NE; Dutka DP
    Circ Cardiovasc Interv; 2011 Jun; 4(3):266-72. PubMed ID: 21586690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.
    McCormick LM; Hoole SP; White PA; Read PA; Axell RG; Clarke SJ; O'Sullivan M; West NEJ; Dutka DP
    JACC Cardiovasc Interv; 2015 Feb; 8(2):292-301. PubMed ID: 25700752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
    Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
    Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.
    Wu T; Bound MJ; Zhao BR; Standfield SD; Bellon M; Jones KL; Horowitz M; Rayner CK
    Diabetes Care; 2013 Jul; 36(7):1913-8. PubMed ID: 23359361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
    Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
    J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells.
    Huang CY; Shih CM; Tsao NW; Lin YW; Huang PH; Wu SC; Lee AW; Kao YT; Chang NC; Nakagami H; Morishita R; Ou KL; Hou WC; Lin CY; Shyu KG; Lin FY
    Br J Pharmacol; 2012 Dec; 167(7):1506-19. PubMed ID: 22788747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
    Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
    Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.